FDA panel OKs vaccine for Lyme
Article Abstract:
SmithKline of Philadelphia, PA, has secured the approval of a US Food and Drug Administration advisory committee for Lymerix, an experimental vaccine against Lyme disease. The committee unanimously concluded the new vaccine was safe and effective against the potentially debilitating disease. Lymerix requires a series of three shots over 12 months to take effect and offers hope that Lyme disease can be eliminated before it gains foothold in the body. Lymerix, which is still subject to FDA approval, is a genetically engineered version of a protein found on the surface of the Lyme bacterium.
Comment:
Secures safety and effectiveness approval of FDA advisory committee for Lymerix, an experimental vaccine against Lyme disease
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Sharp drug price boosts anger users, lawmakers
Article Abstract:
Escalating prices of medication in some parts of the US have alarmed consumers and prompted legislators to call for an investigation. In Pennsylvania, for example, the price of a prescription tranquilizer manufactured by Mylan Pharmaceuticals Inc. has increased by 490%, provoking the state's House of Representatives to pass a resolution to probe the price increase of lorazepam, the drug's generic name, and other generic drugs. The federal government has largely blamed a 0.02% increase in producer price index in May 1998 for the increases.
Comment:
Escalating prices of medication in some parts of US alarm consumers and prompt legislators to call for an investigation
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Diet-drug suit heading for trial in New Jersey
Article Abstract:
American Home Products Corp. will face a trial in New Jersey to decide whether the drug firm must pay for a medical monitoring program for New Jersey state residents who had taken the anti-obesity drugs Redux and Pondimin. Wyeth-Ayerst Laboratories, which is a subsidiary of American Home, had manufactured the controversial diet drugs which have been used by about 6 million patients in the U.S. A U.S. District Court in Philadelphia is hearing evidence to certify a nationwide class for a medical monitoring lawsuit.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Bar owners sue over ATM machine leases. Advanta shares surge after news of settlement
- Abstracts: Centocor wins FDA approval for a third medicine. Anticancer drug, created at Penn, nears approval
- Abstracts: Nobel Education plans its first charter school. Pa. seeks to boost telecom services
- Abstracts: Cigna changes insurance focus to boost profit. Sovereign to establish official headquarters here. Cigna may shun a merger and stay put
- Abstracts: Pa.'s pact with a check-casher. Shares of bank in probe lose 2.7%. Nationwide to set up fund in area